Garry P. Nolan, PhD
Peter Relan, MS
Garry P. Nolan, PhD
Dr. Nolan is a Professor of Microbiology and Immunology in the Baxter Laboratory for Stem Cell Biology at the Stanford University School of Medicine and serves as the Director of the Stanford NHLBI Proteomics Center, as well as Faculty Chair of the Stanford Shared FACS Facility. Dr. Nolan received his PhD from the Department of Genetics at Stanford at the laboratory of Leonard and Lee Herzenberg, and his BS in Genetics from Cornell University. Dr. Nolan was a postdoctoral fellow in the laboratory of Dr. David Baltimore at MIT and Rockefeller University, where he cloned NF-KB p65 and developed novel retroviral transfer technologies.
Dr. Nolan is the author of over 140 peer-reviewed papers and holds numerous issued patents. He is the recipient of several prestigious awards and was honored as one of the top 25 inventors at Stanford University. He was a Hume Faculty Scholar (1993-98), Trustee of the Leukemia Society of America (1995-98), Burroughs Welcome Fund New Investigator Awardee (1996-2000), HHMI Junior Faculty Scholar Awardee, and Leukemia and Lymphoma Society Stohlman Scholar (2000), among others. Dr. Nolan is the scientific founder of Nodality, Inc., a Kleiner-Perkins, TPG, and Maverick Investments-backed biotechnology company as well as Rigel, Inc., a publicly traded company (NASDAQ: RIGL).
Peter Relan, MS
Peter brings 25 years of technology, executive management and serial entrepreneurship experience from Silicon Valley companies. He has been involved in the Internet since 1983 (even before the Web came along). Most recently, he developed the technology for an internet fraud detection system and sold his company, Business Signatures, to a public software company. Peter received his BS from UCLA and then spent several years at Hewlett Packard developing the HP OpenView platform. After receiving his MS from Stanford University, Peter managed the Internet Division and Oracle Application Server for Oracle. Peter was also the founding CTO of WebVan Group, which filed for the largest IPO in Silicon Valley and was subsequently sold to Kaiser Permanente for its sophisticated technology engine, which is currently used to distribute and deliver drugs, medicines and medical supplies to all Kaiser Permanente hospitals. In addition to Cytobank, he serves on the advisory boards of ThreatMetrix, CIIS, Billeo, and Tugboat Ventures. Peter has founded his own incubator, YouWeb, and is also the Executive Chairman of Sibblingz.